This is the authors' abstract. We don't add key points for this paper.
Introduction Dipeptidyl-peptidase-4 (DPP4) inhibition may increase angioedema risk through bradykinin-mediated pathways, a mechanism shared by renin-angiotensin-aldosterone system inhibitors (RAASi). Given the frequent co-prescribing of these therapies in older adults, we compared angioedema risk following DPP4 inhibitor (DPP4i) initiation versus sodium-glucose cotransporter 2 inhibitor (SGLT2i) initiation, overall, and by concomitant RAASi use.Research design and methods We conducted an active-comparator, new-user cohort study using Medicare fee-for-service data (2013–2021) among older adults with type 2 diabetes initiating DPP4i versus SGLT2i. Analyses were conducted overall and within prespecified subgroups defined by concomitant RAASi use, with secondary stratification by ACE inhibitor and angiotensin II receptor blocker use. The primary outcome was angioedema. Inverse probability of treatment weighting (IPTW) adjusted for >100 covariates; weighted cumulative incidence, risk differences (RDs), and risk ratios (RRs) at 365 days were estimated.Results At 365 days, the weighted cumulative incidence of angioedema was 2.49 versus 1.80 per 1000 patients among DPP4i and SGLT2i initiators, respectively (RD 0.70 per 1000, 95% CI 0.23 to 1.15; RR 1.38, 95% CI 1.09 to 1.75). Among concomitant RAASi users, risks were 2.56 versus 1.90 (RD 0.67, 95% CI −0.01 to 1.34; RR 1.35, 95% CI 0.97 to 1.89), and among non-users, risks were 1.89 versus 1.44 (RD 0.45, 95% CI −0.28 to 1.18; RR 1.31, 95% CI 0.84 to 2.06). There was no evidence of effect modification by RAASi use (p=0.92). Findings were generally consistent across sensitivity and subgroup analyses.Conclusion DPP4i initiation was associated with a small absolute increase in angioedema risk versus SGLT2i initiation (~1 additional event per 1450 patients treated for 1 year). There was no evidence that this association differed by concomitant RAASi use on the relative risk scale, although the absolute excess was numerically greater among RAASi users, who had a higher underlying risk of angioedema.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Alkhalaf et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: